导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.92% | 1783/4773 |
| 近一周 | -3.17% | 3817/5462 |
| 近一月 | -9.92% | 4929/5421 |
| 近一季 | -18.61% | 4737/5209 |
| 近半年 | -1.22% | 1514/4920 |
| 近一年 | 6.48% | 1456/4366 |
| 近两年 | 110.35% | 475/2954 |
| 近三年 | 65.53% | 370/2253 |
| 成立以来 | 70.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.59% 1872/4961 |
35.18% 923/5312 |
- - |
- - |
| 2025 | 48.96% 502/4813 |
-1.54% 2687/3635 |
3.28% 1069/4076 |
47.70% 434/4524 |
-0.82% 2659/4813 |
| 2024 | 15.00% 979/3463 |
-3.57% 1524/2808 |
-6.27% 1899/3014 |
27.96% 202/3129 |
-0.57% 1466/3463 |
| 2023 | -17.74% 1757/2656 |
2.29% 1382/2280 |
-6.85% 1726/2385 |
-8.87% 1740/2515 |
-5.26% 1303/2655 |
| 2022 | -27.76% 1506/2207 |
-19.00% 1420/1919 |
5.59% 864/2016 |
-17.56% 1615/2113 |
2.45% 934/2208 |
| 2021 | 12.51% 381/1822 |
-6.37% 998/1255 |
25.27% 91/1330 |
-6.25% 909/1466 |
2.33% 620/1822 |
| 2020 | 63.91% 102/1250 |
4.27% 78/1028 |
28.81% 92/1067 |
6.25% 862/1164 |
14.85% 245/1184 |
| 2019 | 42.33% 216/1092 |
33.53% 134/739 |
-9.67% 681/788 |
7.39% 90/850 |
9.88% 182/918 |
| 2018 | -26.33% 381/834 |
- - |
-14.30% 487/631 |
-11.21% 571/660 |
-10.60% 206/682 |
| 2017 | -8.78% 530/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方创业板ETF联接A VS. 长安沪深300非周期A(740101) |